Physician

Rony M Abou-Jawde, MD

According to 2025 Medicare claims, Rony Abou-Jawde, MD (NPI: 1548226541) practices hematology/oncology in the St. Joseph, MO-KS market, with the plurality of this provider's patient population coming from Buchanan, MO. This provider's primary affiliated billing organization is HEARTLAND REGIONAL MEDICAL CENTER (NPI: 1538200357; TIN: 440545289) and primary practice location at 64507-2518. Abou-Jawde is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Abou-Jawde's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,053 traditional Medicare patients, billed 6,057 HCPCS/CPT codes, and received $316,513 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,247 prescription claims across 619 beneficiaries totaling $10,287,871 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 40 claims. Open Payments data shows 24 records totaling $2,042. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $674,988 to $316,513. In contrast, Part D prescription costs have moved sharply higher in recent years, from $1,782,104 to $10,287,871. For DME billing, this smaller-volume category did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	753	39,262	$674,988
2016	752	39,682	$613,671
2017	828	46,582	$831,198
2018	859	64,677	$1,161,105
2019	947	50,888	$1,091,046
2020	1,018	38,413	$955,866
2021	923	5,839	$295,880
2022	1,080	7,953	$324,125
2023	1,014	7,960	$320,369
2024	1,053	6,057	$316,513

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	318	2,262	$1,782,104
2016	321	2,616	$2,867,403
2017	330	2,789	$3,196,317
2018	364	2,916	$3,341,497
2019	379	2,924	$4,087,452
2020	429	3,218	$4,313,947
2021	484	3,420	$6,544,143
2022	545	3,555	$8,093,785
2023	610	3,699	$7,390,855
2024	619	4,247	$10,287,871

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	129	$53,619
2016	N/R	36	$1,556
2017	N/R	77	$6,266
2018	N/R	25	$1,374
2019	N/R	12	$2,856
2020	N/R	30	$2,521
2021	N/R	51	$2,977
2022	N/R	71	$3,106
2023	N/R	98	$17,739
2024	11	40	$2,374

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	197	370	$102
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	124	275	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	864	2,770	$67
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	135	414	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	276	378	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	106	2,849	$1,526,260
Xtandi	Enzalutamide	106	3,180	$1,346,626
Revlimid	Lenalidomide	72	1,974	$1,197,417
Calquence	Acalabrutinib Maleate	78	2,340	$1,186,294
Cabometyx	Cabozantinib S-Malate	36	1,080	$952,721

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	11	11	$1,557
J8700	Temozolomide, oral, 5 mg	N	N/R	11	$591
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	18	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	21	$404	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$1,638	Celgene Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rony M. Abou-Jawde, MD?

Tedicare shows public-source Medicare data for Rony M. Abou-Jawde, MD (NPI 1548226541), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rony M. Abou-Jawde, MD have ACO affiliation data?

Rony M. Abou-Jawde, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Rony M. Abou-Jawde, MD?

Rony M. Abou-Jawde, MD is linked to HEARTLAND REGIONAL MEDICAL CENTER (billing NPI 1538200357) in the available physician profile data.

Does Rony M. Abou-Jawde, MD have Open Payments data?

Rony M. Abou-Jawde, MD has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.